A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

NCT07393321 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer

Interventions

DRUG: Placebo + fulvestrant
DRUG: NTQ1062+Fulvestrant

Sponsor

Nanjing Chia-tai Tianqing Pharmaceutical